ELSEVIER
SAUNDERS

Obstet Gynecol Clin N Am
31 (2004) 981–1006

OBSTETRICS AND
GYNECOLOGY
CLINICS
OF NORTH AMERICA

Cumulative Index 2004

Volume 31

March	ULTRASOUND IN OBSTETRICS, pages 1–222
June	MANAGEMENT OF THE HIGH-RISK PREGNANCY, pages 223–468
September	ADVANCES IN LAPAROSCOPY AND HYSTEROSCOPY TECHNIQUES, pages 469–726
December	ENDOCRINOLOGY OF PREGNANCY, pages 727–1006

Note: Page numbers of article titles are in **boldface** type.

A

Abdomen, ultrasonography of, for fetal anomalies, 43–44

Abdominal cerclage, for cervical incompetence, 497, 499
laparoscopic, for cervical incompetence. *See* Cervical incompetence.

Abdominal hysterectomy, versus laparoscopic hysterectomy, 526–528

Abdominal wall defects, and umbilical cord abnormalities, 188
fetal, screening for, 868–869

Abnormal uterine bleeding, endometrial ablation for, **687–704**
as alternative to hysterectomy, 525
Cavaterm systems in, 694–695
contraindications to, 689, 690
cryoablation in, 697
Her Option cryoablation system in, 697–698
HydroThermAblator system in, 696–697
indications for, 689
lasers in, 689–690
loop electrocoagulation in, 690
microwaves in, 699–700
NovaSure system in, 698–699
patient selection for, 688
preoperative preparation for, 688–689
rollerblade electrocoagulation in, 690–692
Thermablate EAS system in, 695–696
ThermaChoice systems in, 692–694
transcervical resection in, 690
with hysteroscopic myomectomy, 679
flexible hysteroscopy of, **655–668**
complications of, 662
distention media in, 664
documentation in, 661–662
failure of, 662–663
indications for, 656–657
instrumentation for, 657–658
outpatient, 664–666
pain and analgesia in, 665–666
patient counseling for, 658
postoperative care for, 662
technique for, 659–661
timing of, 659
versus rigid hysteroscopy, 663

Abortion, recurrent, luteal phase defect and, 733–735

Abruption, placental, ultrasonography of, 194

Acardiac twins, ultrasonography of, 150–151

Accolate, for asthma, in pregnancy, 404

Acid-base changes, in pregnancy, and laparoscopic surgery, 489

Acromegaly, in pregnancy, 260–261, 885

Activated protein C resistance, in pregnancy, 326

Activin, monitoring of, in first trimester, 769

Acute chest syndrome, in pregnancy, 294

0889-8545/04/$ – see front matter © 2004 Elsevier Inc. All rights reserved.
doi:10.1016/S0889-8545(04)00113-5

Addison's disease, and maternal adrenals, 830
in pregnancy, 278, 887–888

Adhesions, pelvic, laparoscopic surgery for, 622–623

Adnexal masses, differential diagnosis of, 477
laparoscopic surgery for, in children and adolescents, 477–479
in second trimester, 487
robotic laparoscopic surgery for, 605

Adrenal artery, fetal, Doppler velocimetry of, 205

Adrenal diseases, in pregnancy, 277–280, 887–888

Adrenal insufficiency, and maternal adrenals, 830

Adrenals, fetal, in pregnancy, 817–827
adrenocorticotropic hormone and, 821
and placental estrogen biosynthesis, 822–824
and regulation of parturition, 824
congenital adrenal hyperplasia and, 825–826
congenital adrenal hypoplasia and, 824–825
development of, 818
placental corticotropin-releasing hormone and, 821–822
placental enzymatic deficiencies and, 826–827
steroidogenic enzymes in, 818–820
structure of, 817
maternal, in pregnancy, 827–831
adrenal androgens and, 829
adrenal insufficiency and, 830
Cushing's syndrome and, 830–831
glucocorticoid hormones and, 827–829
mineralocorticoids and, 829
morphologic changes in, 827
pheochromocytomas and, 831

Adrenocortical hormone, in pregnancy, 277–278

Adrenocorticotropic hormone, and fetal adrenals, 821

AESOP system, in robotic laparoscopic surgery, 600

β-Agonists, for asthma, in pregnancy, 401–402

Aldosterone, and maternal adrenals, 829

Alloimmune thrombocytopenia, fetal platelet transfusion for, 110

Alocril, for asthma, in pregnancy, 402

Alpha-fetoprotein, evaluation of, chorionic villus sampling in, 105
in screening, for Down syndrome, 866
for neural tube defects, 379, 868
for trisomy 18, 867

Amniocentesis, 101–104
complications of, 103
early in pregnancy, 104
historical aspects of, 101–102
in multiple gestations, 103
in presence of bleeding, 103
in screening, for hemoglobinopathies, in pregnancy, 308
safety of, 103
technique for, 102–103
therapeutic, for twin-to-twin transfusion syndrome, 150

Amnion nodosum, ultrasonography of, 183

Amnioreduction, 111–112
complications of, 112
historical aspects of, 111
safety of, 112
technique for, 111–112

Amniotic band syndrome, ultrasonography of, 181–182

Amniotic fluid, leakage of, amniocentesis and, 103
ultrasonography of, 177–181
for oligohydramnios, 178–180
for polyhydramnios, 180–181
in multiple gestations, 181
to measure volume, 177–178

Amniotic fluid index, in amniotic fluid measurement, 178–181

Amniotic rupture sequence, ultrasonography of, 181–182

Androgen receptor, in genital tract formation, 850

Androgens, and maternal adrenals, 829
role of, in implantation, 757–758

Anemia, thalassemia syndromes and, in pregnancy, 309

Aneuploidy. *See also* Down syndrome.
clubfoot with, 79–80
echogenic bowel with, 64–65
echogenic intracardiac foci with, 74–75
pyelectasis with, 69, 70
screening for, nuchal translucency in, 8
trisomy 18, 867–868

ultrasonography of, **21–33**
in twin gestations, 152–156
trisomy 13, 29–31
central nervous system abnormalities in, 30
heart defects in, 30
midline facial abnormalities in, 30
nuchal thickening in, 31
polydactyly in, 30
renal abnormalities in, 30
trisomy 18, 27–29
choroid plexus cysts in, 29, 86–89
heart defects in, 28
intrauterine growth restriction in, 28
omphalocele in, 28–29
skeletal abnormalities in, 28
trisomy 21. *See* Down syndrome.

Angiotensin-converting enzyme inhibitors, for pre-eclampsia, 235–236

Antibiotics, in hysteroscopic myomectomy, 678

Anticardiolipin antibody, in pregnancy, 360

Anticoagulation, for antiphospholipid syndrome, in pregnancy, 365
for mechanical heart valves, in pregnancy, 436–439

Antiepilepsy drugs, fetal effects of, 374–377

Antihypertensive medications, for pre-eclampsia, 231, 234, 235–236

Antimalarial drugs, for systemic lupus erythematosus, in pregnancy, 353, 355

Antiphospholipid syndrome, in pregnancy, 328–329, 356–365
and pregnancy loss, 357–358
and thrombocytopenia, 359
and thrombosis, 358–359
antibody testing for, 359
anticardiolipin antibody in, 360
lupus anticoagulant in, 328–329, 359–360
management of, 361–365
heparin in, 362–364
intravenous immunoglobulin in, 365
prednisone in, 361–362
pathogenesis of, 361
postpartum care for, 365

Antithrombin III deficiency, in pregnancy, 324

Aortic regurgitation, in pregnancy, 436

Aortic root diameter, in Marfan's syndrome, in pregnancy, 441

Aortic stenosis, in pregnancy, 434–435

Aortic valves, fetal, Doppler velocimetry of, 210

Appearing twin phenomenon, ultrasonography of, 143

Appendectomy, laparoscopic, in children and adolescents, 474–476
in second trimester, 487

Arrhythmias, in pregnancy, 446–448

Arteries, fetal, Doppler velocimetry of, 205–206

Assisted reproductive technology, hormonal supplementation in, 758
luteal phase defect and, 736–737

Asthma, and breast-feeding, 411
in pregnancy, **385–413**
acute management of, 405–407
and labor and delivery, 407, 411
effects on pregnancy/fetal outcome, 393–394
episode prevention in, 398–399
maintenance management of, 399–405
β-agonists in, 401–402
cromones in, 402
fetal ultrasonography in, 400
IgE blockers in, 405
inhaled steroids in, 402–403
ipratropium bromide in, 403
leukotriene modifiers in, 404
pulmonary function tests in, 400
systemic steroids in, 405
theophylline in, 403–404
pathophysiology of, 387, 390–392
early phase, 391
late phase, 391–392
patient education on, 397–398
patient goals in, 395
postpartum care for, 411
pregnancy effects on asthma, 394
pulmonary function tests for, 395, 397
severity of, 392
treatment guidelines for, 395
versus normal airway physiology, 386–387

Atrial fibrillation, in pregnancy, 447

Atrial septal defects, in pregnancy, 441–442

Atrioventricular valves, fetal, Doppler velocimetry of, 209–210

Atrovent, for asthma, in pregnancy, 403

Autoimmune disease, in pregnancy.
See Antiphospholipid syndrome; Systemic lupus erythematosus.

Azathioprine, in pregnancy, after organ transplantation, 419

B

Balloon valvuloplasty, in utero, technique for, 119

Barrier contraceptives, after organ transplantation, 422

Basal body temperature chart, for luteal phase defect, 729–730

Battledore placenta, ultrasonography of, 187

Beta-blockers, for Graves' disease, in pregnancy, 898

Betamethasone, and fetal lung development, 956–957

Biochemical screening, for congenital defects, **857–872**
Down syndrome.
See Down syndrome.
open neural tube and abdominal wall defects, 868–869
trisomy 18, 867–868

Biometry, fetal, in Down syndrome, 25

Biophysical profile, in intrauterine growth restriction, 167–168

Biopsy, endometrial, for luteal phase defect, 730–731, 732, 737
fetal. *See* Fetal biopsy.
placental, chorionic villus sampling in, 106
uterine, hysteroscopy in, 644–645

Bipartite placenta, ultrasonography of, 191

Bipolar surgery. *See* Office hysteroscopy.

β-Blockers, for Graves' disease, in pregnancy, 270

Blood transfusions, for sickle cell syndromes, in pregnancy, 293

Body stalk anomaly, and umbilical cord abnormalities, 188

Brain, ultrasonography of, for fetal anomalies, 39–41

Brain sparing, fetal, in hypoxia, 166

Breast-feeding, after organ transplantation, 427
asthma and, 411
diabetes mellitus and, 924
endocrinology of, **963–979**
galactogogues in, 973
galactokinetic hormones in, 972–974
oxytocin in, 972–974
placental lactogen and growth hormones in, 970–971
prolactin in, 966–970
dopamine and, 968
galactopoiesis in, 971–973
lactogenesis in, 966
mammary gland embryology and, 963–964
mammary gland morphology and, 964–965
mammogenesis in, 965–966
prolactinomas and, 260
seizure disorders and, 380–381

Bromocriptine, for prolactinomas, in pregnancy, 883–884

Budesonide, for asthma, in pregnancy, 403

Burch procedures, for urinary incontinence.
See Urinary incontinence.

C

CA-125, as marker, for ovarian cysts, 583
in screening, for Down syndrome, 860–861

Calcitonin, role of, in implantation, 756

Calcium metabolism, in pregnancy, 275–277

Carbamazepine, for seizure disorders, fetal effects of, 375

Carbon dioxide, in flexible hysteroscopy, 664

Carbon dioxide pneumoperitoneum, in laparoscopic surgery, in second trimester, 490, 492–493

Carbon monoxide, in laparoscopic surgery, in second trimester, 493

Carcinoembryonic antigen, monitoring of, in first trimester, 769

Cardiac disease, in pregnancy, **429–459**
aortic regurgitation, 436
aortic stenosis, 434–435
arrhythmias, 446–448
cardiopulmonary bypass for, 454
congenital heart disease, 439–444
atrial septal defects, 441–442
coarctation of aorta, 440
cyanotic, 443–444
Eisenmenger's syndrome, 442–443
left-to-right shunts, 441
Marfan's syndrome, 440–441

patent ductus arteriosus, 442
ventricular septal defects, 442
endocarditis, prevention of, 448, 451, 454
ischemic heart disease, 445–446
mechanical heart valves, 436–439
mitral regurgitation, 435–436
mitral stenosis, 431–432, 434
and labor management, 434
mitral valve prolapse, 436
peripartum cardiomyopathy, 444–445
pulmonic stenosis, 435
valvular disease, 431

Cardiac function, thalassemia syndromes and, in pregnancy, 301–302

Cardiomyopathy, peripartum, 444–445

Cardiopulmonary bypass, in pregnancy, 454

Cardiotocography, in intrauterine growth restriction, 168–169

Cardiovascular changes, in pregnancy, and laparoscopic surgery, 488

Cardiovascular disease, diabetes mellitus and, 917

Cardiovascular system, fetal, Doppler velocimetry of, 204–206
in pregnancy, 429–431
antepartum changes in, 429–430
intrapartum changes in, 430
postpartum changes in, 431

Cardioverter-defibrillators, implantable, in pregnancy, 447–448

Cavaterm systems, for abnormal uterine bleeding, 694–695

Cavum septum pellucidum, ultrasonography of, for fetal anomalies, 40

Celiac trunk, fetal, Doppler velocimetry of, 205

Cell adhesion molecules, as markers, for implantation, 750

CellCept, in pregnancy, after organ transplantation, 420

Cellular markers, for implantation. *See* Implantation.

Central nervous system abnormalities, in trisomy 13, 30

Cerclage, abdominal, for cervical incompetence, 497, 499
laparoscopic, for cervical incompetence. *See* Cervical incompetence.
cervical, to prevent preterm delivery, 130, 134, 152

Cerebral blood flow, fetal, Doppler velocimetry of, 203–204

Cerebral-umbilical ratios, in Doppler velocimetry, 204

Cervical incompetence, laparoscopic abdominal cerclage for, **497–504**
advantages of, 499–501
pregnancy rate after, 500–501
technique for, 502–503
versus abdominal cerclage, 497, 499

Cervical lacerations, hysteroscopic myomectomy and, 676

Cervical length, and preterm delivery, 127, 129–131, 133–134, 151–152

Cervical stress test, in screening, for preterm delivery, 128–129

Chelation therapy, for thalassemia syndromes, in pregnancy, 309

Chemicals, in tubal sterilization, 708–709

Chemotherapy, fertility preservation after, 611

Chlamydia trachomatis, and ectopic pregnancy, 783

Cholecystectomy, laparoscopic, in second trimester, 487

Cholesterol, in steroid hormone synthesis, in pregnancy, 797–799, 801–803

Cholesterol 20,22 desmolase, in genital tract formation, 846

Chorioangiomas, ultrasonography of, 195

Chorionic villus sampling, 104–106
and isoimmunization, 106
complications of, 105
historical aspects of, 104
in multiple gestations, 105–106
in screening, for Down syndrome, 15
for hemoglobinopathies, in pregnancy, 308
later in pregnancy, 106
safety of, 105
technique for, 104–105

Choroid plexus cysts, diagnosis of, 86
in aneuploidy, 86–89
modifying risk of, 87–89
in Down syndrome, 26
in trisomy 18, 29
management of, 89–91
pathophysiology of, 86
ultrasonography of, 86–91

Chromosomal abnormalities, and intrauterine growth restriction, 162

Chronic pelvic pain. *See also* Endometriosis.
etiology of, in children and adolescents, 480
laparoscopic surgery for, **619–630**
conscious pain mapping for, 626–627
hernias, 624
in children and adolescents, 475, 479–481
ovarian cysts. *See* Ovarian cysts.
ovarian remnants. *See* Ovarian remnants.
pelvic adhesions, 622–623
uterine pain, 625–626
vaginal apex pain, 624–625
varicosities, 626

Circumvallate placenta, ultrasonography of, 192

Cisterna magna, ultrasonography of, for fetal anomalies, 40

Cleft palate, maternal steroid intake and, 405

Clinodactyly, in Down syndrome, 25–26

Clubfoot, diagnosis of, 78–79
etiology of, 76, 78
management of, 79–80
ultrasonography of, 46–47, 76, 78–80
with aneuploidy, 79–80

Coagulation cascade, in pregnancy, and laparoscopic surgery, 488

Coagulopathies, in pregnancy, 323

Coarctation of aorta, in pregnancy, 440

Colony-stimulating factor, as marker, for implantation, 751

Colpopexy, sacral, laparoscopic technique for, 555–557
robotic, 607

Computed tomography, of deep vein thrombosis, in pregnancy, 333
of ovarian cysts, 584
of pulmonary embolism, in pregnancy, 336

Condoms, in contraception, after organ transplantation, 422

Congenital adrenal hyperplasia, and fetal adrenals, 825–826
in pregnancy, 279

Congenital adrenal hypoplasia, and fetal adrenals, 824–825

Congenital heart disease. *See also* Heart defects.
in pregnancy. *See* Cardiac disease.
screening for, Doppler velocimetry in, 209
ultrasonography in, **51–59**
four-chamber view in, 51–54
importance of, 55–56
population for, 56–57
ventricular outflow tract views in, 54–55

Conjoined twins, ultrasonography of, 145–146

Connexins, as markers, for implantation, 755

Contraception, after organ transplantation. *See* Organ transplantation.
diabetes mellitus and, 925
oral, for ovarian cysts, 583–584

Cooley's anemia, in pregnancy, 297–298, 299

Cord blood sampling, in screening, for hemoglobinopathies, in pregnancy, 311–312

Cord occlusion procedures, indications for, 119

Cordocentesis, 106–108
complications of, 108
safety of, 108
technique for, 107–108

Coronary sinus, fetal, Doppler velocimetry of, 206

Corticotropin, in pregnancy, 878–879

Corticotropin-releasing hormone, and initiation of parturition, at term, 937–938
in pregnancy, 878
placental, and fetal adrenals, 821–822
role of, in implantation, 757

Cortisol, and initiation of parturition, at term, 939–940

Coumadin, for mechanical heart valves, in pregnancy, 436–437
for thromboembolic disease, in pregnancy, 338–339

Cromolyn sodium, for asthma, in pregnancy, 402

Cromones, for asthma, in pregnancy, 402

Cryoablation, for abnormal uterine bleeding, 697–698

Cryocoagulation, in tubal sterilization, 708

Culdocentesis, in ectopic pregnancy, 788

Cushing's syndrome, and maternal adrenals, 830–831
in pregnancy, 261–262, 884–885

Cyanotic congenital heart disease, in pregnancy, 443–444

Cyclosporin A, in pregnancy, after organ transplantation, 419–420

CYP21 deficiency, and fetal adrenals, 825–826

Cystectomy, laparoscopic, in children and adolescents, 478–479

Cystic fibrosis, echogenic bowel with, 65

Cystic hygroma, in Down syndrome, 23–24

Cystoceles, laparoscopic surgery for, 561–563

Cysts, choroid plexus. *See* Choroid plexus cysts.
ovarian. *See* Ovarian cysts.
theca lutein, ultrasonography of, 195–196
umbilical cord, ultrasonography of, 189

Cytochrome P450, in steroid hormone synthesis, in pregnancy, 797–798, 801–803

Cytokines, as markers, for implantation, 751–752
in ectopic pregnancy, 781–783

Cytomegalovirus infections, congenital, echogenic bowel with, 65

D

da Vinci system, in robotic laparoscopic surgery, 600, 601–602, 605–607

Dax-1, in ovarian differentiation, 842–843
in testicular differentiation, 841

Deep vein thrombosis, in pregnancy, 332–333

Delivery, asthma and, 407, 411
mitral stenosis and, 434
timing of, for diabetic patients, 251–253, 924
for organ transplant patients, 426–427
for pre-eclampsia, 228, 231, 236–237
for sickle cell syndromes, 295
for thalassemia syndromes, 302
for thromboembolic disease, 339–340

Deoxycorticosterone, and maternal adrenals, 829

Descending aorta, fetal, Doppler velocimetry of, 205

Dexamethasone, and fetal lung development, 956–957

Diabetes insipidus, in pregnancy, 264, 886–887

Diabetes mellitus, in pregnancy, **243–256, 907–932**
and cardiovascular disease, 917
and contraception, 925
and fetal anomalies, 247, 917–919
hypoglycemia, 918–919
macrosomia, 169–170, 252–253, 918
neurodevelopmental, 919
polyhydramnios, 918
respiratory distress syndrome, 919
shoulder dystocia, 252–253, 918
and lactation, 924
and macroangiopathy, 912
and microangiopathy, 911–912
and nephropathy, 916
and neuropathy, 916–917
and obstetic complications, 917
and retinopathy, 915–916
carbohydrate metabolism and, 907–909
classification of, 910–911, 915
definition of, 909
diagnosis of, 909–910, 926
fetal assessment in, 923–924
glucose challenge test in, 245
glucose tolerance test in, 246, 253, 909–910
glycemic control in, 921–923
HbA_{1c} levels in, 247, 913–914
insulin in, 250–251, 912–913, 922–923, 924
management of, 926–927
postpartum care for, 253–254, 924–925, 927
pre-pregnancy counseling for, 920–921
prenatal care for, 248–241
diet in, 248–249
exercise in, 249
glucose monitoring in, 249–251
patient education in, 249
prenatal testing in, 251
screening for, 244–246, 926
sulfonylurea drugs for, 251
timing and method of delivery in, 251–253, 924
type 2, 919–920

Diaphragms, in contraception, after organ transplantation, 422

Dihydrotestosterone, in genital tract formation, 849–850

Distention media, in hysteroscopic myomectomy, 676, 679

DNA diagnosis, in screening, for hemoglobinopathies, in pregnancy, 309

Dopamine, and prolactin, in breast-feeding, 968

Dopamine agonists, for prolactinomas, in pregnancy, 883–884

Doppler velocimetry, of fetus, **201–214**
- Doppler indices for, 202
- for adrenal artery, 205
- for aortic and pulmonary valves, 210
- for atrioventricular valves, 209–210
- for celiac trunk, 205
- for coronary sinus, 206
- for descending aorta, 205
- for ductus venosus, 206–209
- for femoral artery and external iliac artery, 206
- for intrauterine growth restriction, 165–167, 202–204, 206, 209–210
- for renal artery, 205
- for single umbilical artery, 85–86
- for splenic artery, 205
- for superior cerebellar artery, 206
- for superior mesenteric artery, 205
- to predict congenital heart disease, 209
- to predict hematocrit, 210
- of placenta, 196–197

Down syndrome, 22–27. *See also* Aneuploidy.
- advanced maternal age and, 22
- choroid plexus cysts in, 26
- clinical features of, 22
- clinodactyly in, 25–26
- cystic hygroma in, 23–24
- echogenic bowel in, 26–27, 64–65
- echogenic intracardiac foci in, 26, 74–75
- etiology of, 22
- femur length in, 25
- fetal biometry in, 25
- gastrointestinal abnormalities in, 23
- heart defects in, 23
- humerus length in, 25
- nuchal thickening in, 25
- pyelectasis in, 27
- risk of, 24–25
- screening for, **1–20,** 857–867
  - CA-125 in, 860–861
  - chorionic villus sampling in, 15
  - cost effectiveness of, 16
  - current and future status of, 16–17
  - fetal ductus venosus flow in, 11–12
  - fetal nasal bone in, 12–13
  - human chorionic gonadotropin in, 859–860, 864–866
  - in twin gestations, 152–155
  - inhibin-A in, 858–859
  - invasive trophoblast antigen in, 861–863
  - nuchal translucency in, 2–3, 6–8, 154–155
    - and second-trimester screening, 14–15
    - in multiple gestations, 8
    - interpretation of, 14
    - quality control in, 13–14
    - with maternal serum markers, 9, 11
  - patient counseling in, 16
  - plasma protein-A in, 865–866
  - quad screen in, 1
  - ultrasonography markers in, 24–27
  - urea-resistant neutrophil alkaline phosphatase in, 861

Ductus venosus flow, fetal, Doppler velocimetry of, 206–209
- in screening, for aneuploidy, 11–12

Ductus venosus waveforms, in intrauterine growth restriction, 167

Duodenal atresia, in Down syndrome, 23

Dysfibrinogenemia, in pregnancy, 328

E

Echocardiography, of single umbilical artery, 85

Echogenic bowel, diagnosis of, 62–63
- grading of, 62
- management of, 67
- pathophysiology of, 62
- prognosis for, 66–67
- ultrasonography of, 44, 61–67
  - transducer frequency and, 63
- with aneuploidy, 26–27, 64–65
- with congenital infections, 65
- with cystic fibrosis, 65
- with intra-amniotic bleeding, 66
- with intrauterine growth restriction, 66

Echogenic intracardiac foci, management of, 76
- ultrasonography of, 73–76
- with aneuploidy, 26, 74–75

Ectopic pregnancy, **779–794**
- diagnosis of, 786–788
- etiology of, 779–786
  - cytokines in, 781–783
  - environmental factors in, 785–786

hormonal changes and motility, 785
immunologic factors in, 784
implantation window in, 780–781
inflammation in, 783
leukemia inhibitory factor in, 782
sperm and genetic defects in, 786
trophoblast invasion in, 784–785
management of, 788–791
expectant, 789
medical, 789–790
surgical, 790–791

Eisenmenger's syndrome, in pregnancy, 442–443

Electrocoagulation, for abnormal uterine bleeding, 690–692
in tubal sterilization, 707–708

Embolism, gas, hysteroscopic myomectomy and, 676

Embolization, uterine artery, as alternative to hysterectomy, 524
as alternative to hysteroscopic myomectomy, 679–680

Embryo cryopreservation, with in vitro fertilization, in fertility preservation, 612

Endocardial cushion, in Down syndrome, 23

Endocarditis, prevention of, in pregnancy, 448, 451, 454

Endocrine disorders, in pregnancy, **257–285, 893–905**
acromegaly, 260–261, 885
adrenocortical hormone changes, 277–278
congenital adrenal hyperplasia, 279
Cushing's syndrome, 261–262, 884–885
diabetes insipidus, 264, 886–887
antedating pregnancy, 264
diabetes mellitus.
See Diabetes mellitus.
fetal thyroid physiology and, 895–896
functionless pituitary tumors, 262
Graves' disease, 269–270, 897–899
Hashimoto's thyroiditis, 901
hirsutism and virilization, 280
hyperthyroidism, 269–270, 896–899
fetal and neonatal, 270
related to human chorionic gonadotropin, 270–271
hypoparathyroidism, 276–277
hypopituitarism, 262–263
hypothyroidism, 271–272, 900–901
fetal, 272–273
iodine deficiency and goiter, 266, 271
lymphocytic hypophysitis, 262–263
malignant tumors, 273
maternal thyroid physiology, 265
non-toxic goiter, 273
normal thyroid physiology, 265
osteoporosis, 277
pheochromocytomas, 279–280
placental-fetal thyroid physiology, 267
placental transfer of drugs affecting thyroid, 267
postpartum Graves' disease, 902–903
postpartum thyroid disease, 273–274
postpartum thyroiditis, 901–902
primary adrenocortical insufficiency, 278
primary hyperaldosteronism, 278
primary hyperparathyroidism and hypercalcemia, 275–276
prolactinomas, 258–260, 882–884
and breast feeding, 260
effect on pregnancy and fetus, 259
management of, 260, 883–884
postpartum care for, 260
pregnancy effect on, 259–260
Sheehan's syndrome, 262, 885–886
thyroid function, drugs and, 268
laboratory evaluation of, 267–268
thyroid nodules, 273
vasopressin deficiency, 263–264
versus normal thyroid physiology, 893–895

Endometrial ablation, for abnormal uterine bleeding. *See* Abnormal uterine bleeding.

Endometrial biopsy, for luteal phase defect, 730–731, 732, 737

Endometrial receptivity, luteal phase defect and, 737–738, 748–749

Endometriosis. *See also* Chronic pelvic pain.
classification of, 570–571
hourglass-shaped lesions, 571
posterior vaginal fornix lesions, 571
rectovaginal septum lesions, 571
clinical features of, 571–573
diagnosis of, 570

laparoscopic surgery for, **567–580,** 620–622
complications of, 576–577
in children and adolescents, 479–481
technique for, 573–576
of bladder and ureter, 577
of sidewall and ureter, 577–578
retroperitoneal hypothesis of, 567–570
transvaginal hydrolaparoscopy for, 635–636

Endometrium, role of, in implantation, 746–747

Enteroceles, laparoscopic surgery for, 553, 554–555, 557, 560

Enzyme deficiencies, placental, and fetal adrenals, 826–827

Epilepsy, in pregnancy. *See* Seizure disorders.

Essure system, in tubal sterilization. *See* Tubal sterilization.

Estrogen, and initiation of parturition, at term, 940–942
in steroid hormone synthesis, in pregnancy, 798
monitoring of, in first trimester, 768

Estrogen biosynthesis, placental, fetal adrenals and, 822–824

Estrogen receptors, role of, in implantation, 747

Eurofetus trial, of ultrasonography, of fetal anomalies, 37–38

Exercise, for diabetes mellitus, in pregnancy, 249

External iliac artery, fetal, Doppler velocimetry of, 206

Extremities, ultrasonography of, for fetal anomalies, 45–47

F

Face, ultrasonography of, for fetal anomalies, 41

Facial abnormalities, in trisomy 13, 30

Factor V Leiden, in pregnancy, 326

Femoral artery, fetal, Doppler velocimetry of, 206

Femur length, in Down syndrome, 25

Fertility preservation, after chemotherapy, 611
after hysteroscopic myomectomy, 675
after radiation therapy, 611
in vitro fertilization and embryo cryopreservation in, 612
in vitro maturation of immature oocytes in, 612
laparoscopic surgery in, **611–618**
for ovarian cryopreservation, 614–615
for ovarian transposition, 613–614
oocyte cryopreservation in, 612

Fetal anomalies, epidemiology of, 35–36
ultrasonography of, **35–50**
abdominal anomalies, 43–44
adverse effects of, 48
Eurofetus trial of, 37–38
extremity anomalies, 45–47
head and brain anomalies, 39–41
RADIUS trial of, 36–38, 52–53
sensitivity of, 36–38
spinal anomalies, 45
standards for, 38–39
thoracic and cardiac anomalies, 42–43
timing of, 38
umbilical cord anomalies, 47–48
urinary tract anomalies, 44–45

Fetal anticonvulsant syndrome, diagnosis of, 376

Fetal biopsy, 108–109
of kidneys, 109
of muscles, 108–109
of skin, 109

Fetal growth and well-being, **159–176**
intrauterine growth restriction, 160–169
biophysical profile in, 167–168
cardiotocography in, 168–169
chromosomal abnormalities and, 162
diagnosis of, 163–164
Doppler velocimetry of, 165–167, 202–204, 206, 209–210
echogenic bowel with, 66
etiology of, 161–162
familial factors in, 163
in trisomy 18, 28
intrauterine infections and, 162
management of, 164
maternal factors in, 162–163
maternal systemic lupus erythematosus and, 350
symmetric versus asymmetric, 164
weight prediction formulae in, 161
macrosomia, 169–171, 918
and shoulder dystocia, 169–170, 918
maternal diabetes and, 169–170, 252–253, 918
ultrasonography of, 170–171
normal growth, 159–160

Fetal hormones, and sexual differentiation. *See* Sexual differentiation.

Fetal loss, amniocentesis and, 103
chorionic villus sampling and, 105
cordocentesis and, 108
multifetal reduction and, 113–114
selective termination and, 115

Fetal lung development, delayed, maternal diabetes mellitus and, 252
hormones and, **949–961**
antenatal glucocorticoids, 950–957
and complicated pregnancies, 953
and neonatal morbidity and mortality, 952–953
and respiratory distress syndrome, 952
betamethasone versus dexamethasone, 956–957
NIH Consensus Conference on, 953–955
repeat course of, 955–956
thyrotropin-releasing hormone and, 957–958
thyroid hormones, 950–951
stages of, 949–950

Fetal membranes, ultrasonography of, 181–183
for amnion nodosum, 183
for amnion rupture sequence, 181–182

Fetal transfusions, 109–111
complications of, 111
indications for, 110
safety of, 111
technique for, 110–111

Fetocentesis, technique for, 115–116

Fibroids, classification of, 674
hysteroscopic myomectomy for, **669–685**
alternatives to, 679–680
laparoscopic myomectomy, 680
uterine artery embolization, 679–680
vaginal myomectomy, 680
antibiotics in, 678
bleeding pattern and, 671, 674
complications of, 675–677
cervical lacerations, 676
distention media and, 676
gas embolism, 676
hemorrhage, 675–676
infections, 677
missed leiomyosarcoma, 677
pain, 677
perforation, 676
uterine rupture, 677
distention media in, 679
endometrial ablation with, 679
historical aspects of, 669–670
patient counseling for, 671
patient selection for, 670–671
pregnancy rates after, 675
preoperative gonadotropin-releasing hormone analogues in, 678
preoperative imaging in, 677–678
reoperation rate after, 674
results of, 671
ultrasonography guidance in, 678

FK506, in pregnancy, after organ transplantation, 420

Flexible hysteroscopy, of abnormal uterine bleeding. *See* Abnormal uterine bleeding.

Flow velocity waveforms. *See* Doppler velocimetry.

Folic acid supplementation, for seizure disorders, in pregnancy, 379

Follicle-stimulating hormone, in pregnancy, 881–882

Four-chamber views, in screening, for congenital heart disease, 51–54

Fruit signs, in ultrasonography, of fetal skull, 40–41

G

Gabapentin, for seizure disorders, fetal effects of, 376

Galactogogues, in breast-feeding, 973

Galactokinetic hormones, in breast-feeding, 972–974

Galactopoiesis, in breast-feeding, 971–973

Gas embolism, hysteroscopic myomectomy and, 676

Gastrointestinal abnormalities, in Down syndrome, 23

Gastrointestinal changes, in pregnancy, and laparoscopic surgery, 489

Gastroschisis, and umbilical cord abnormalities, 188

Genital tracts, formation of, fetal hormones and. *See* Sexual differentiation.

Gestational hypertension, management of, 237

Gestational hyperthyroidism, recurrent, 271

Gestational transient thyrotoxicosis, clinical features of, 270

Gestational trophoblastic disease, and hyperthyroidism, 270–271

Glucocorticoids, and maternal adrenals, 827–829
antenatal, and fetal lung development. *See* Fetal lung development.
for congenital adrenal hyperplasia, in pregnancy, 279

Glucose challenge test, for diabetes mellitus, in pregnancy, 245

Glucose control, in pregnancy, 913–914

Glucose monitoring, in diabetes mellitus, in pregnancy, 249–251

Glucose tolerance test, for diabetes mellitus, in pregnancy, 246, 909
postpartum, 253

Glyburide, for diabetes mellitus, in pregnancy, 251

Glycemic control, in labor and delivery, 924
in pregnancy, 921–923

Goiter, in pregnancy, 266, 273

Gonadal development, in sexual differentiation, 838

Gonadotropin-releasing hormone analogues, in hysteroscopic myomectomy, 678

Gonadotropins, in pregnancy, 881–882

Graves' disease, in pregnancy, 269–270, 897–899
postpartum, 902–903

Growth factors, as markers, for implantation, 754–755

Growth hormones, excess secretion of, in pregnancy, 260–261
in breast-feeding, 970–971
in pregnancy, 879–880

H

Hashimoto's thyroiditis, in pregnancy, 901

Hb Lepore, in pregnancy, 298

HbA_{1c} levels, in diabetes mellitus, in pregnancy, 247, 914

Head, ultrasonography of, for fetal anomalies, 39–41

Heart, ultrasonography of, for fetal anomalies, 42–43

Heart defects. *See also* Congenital heart disease.
in Down syndrome, 23
in trisomy 13, 30
in trisomy 18, 28

Heart rate, fetal, in intrauterine growth restriction, 168–169

HELLP syndrome, and hypertension, 234

Hemangiomas, placental, ultrasonography of, 195
umbilical cord, ultrasonography of, 190

Hematocrit, fetal, prediction of, Doppler velocimetry in, 210

Hematomas, umbilical cord, ultrasonography of, 190

Hemoglobin Bart's disease, in pregnancy, 303–304

Hemoglobin E disease, in pregnancy, 296, 298

Hemoglobin H disease, in pregnancy, 303–305

Hemoglobin SC disease, in pregnancy, 295–296

Hemoglobinopathies, in pregnancy, **287–317**
carrier screening for, 305–309
counseling for, 309–310
DNA diagnosis of, 309
erythrocyte function in, 289–290
genetic issues in, 305
hemoglobin synthesis and structure in, 287–289
maternal factors in, 290–291
newborn screening in, 312–313
perinatal therapy for, 310–312
cord blood collection in, 311–312
human leukocyte antigen typing in, 311–312
prenatal diagnosis of, 307–308
amniocentesis in, 308
chorionic villus sampling in, 308
ultrasonography in, 307–308
sickle cell syndromes, 291–296
acute chest syndrome, 294
and timing of delivery, 295
carrier screening for, 306
fetal surveillance in, 293
hemoglobin SC disease, 295–296
management of, 293
prenatal screening for, 307
sickle cell crisis, 293–294
sickle cell disease, 292
sickle cell–β-thalassemia, 296
sickle cell–hemoglobin E disease, 296

sickle trait, 292
urologic complications of, 294–295
thalassemia syndromes, 296–305
and anemia, 301
and cardiac function, 301–302
and infertility, 299–300
carrier screening for, 306
chelation therapy for, 301
counseling for, 310
DNA diagnosis of, 309
Hb Lepore, 298
hemoglobin E disease, 296, 298
hemoglobin H disease, 303–305
pathophysiology of, 296–298
preconception evaluation for, 299–302
prenatal care for, 300–301
prenatal screening for, 307
β-thalassemia, 297
β-thalassemia intermedia, 298, 299
β-thalassemia major, 297–298, 299
β-thalassemia minor, 297, 298–299
α-thalassemia trait, 302–303, 304
timing of delivery for, 302
with sickle cell syndromes, 296

Hemorrhage, hysteroscopic myomectomy and, 675–676

Heparin, for antiphospholipid syndrome, in pregnancy, 362–364
for mechanical heart valves, in pregnancy, 437, 439
for thromboembolic disease, in pregnancy, 336–338

Her Option cryoablation system, for abnormal uterine bleeding, 697–698

Hernias, and pelvic pain, laparoscopic surgery for, 624

High-density lipoprotein, in steroid hormone synthesis, in pregnancy, 799

Hirsutism, in pregnancy, 280

HIV transmission, amniocentesis and, 103

Homeobox genes, as markers, for implantation, 752–754

Human chorionic gonadotropin, and hyperthyroidism, in pregnancy, 270–271
in ectopic pregnancy, 787–790
in screening, for Down syndrome, 9, 154–155, 859–860, 864–866
for trisomy 18, 867–868
in steroid hormone synthesis, in pregnancy, 798
monitoring of, in first trimester, 768–769
role of, in implantation, 756–757

Human chorionic somatomammotropin, in breast-feeding, 970–971

Human leukocyte antigen tests, in screening, for hemoglobinopathies, in pregnancy, 311–312

Human placental lactogen, in breast-feeding, 970–971

Humerus length, in Down syndrome, 25

Hydatidiform mole, ultrasonography of, 195

Hydrocortisone, for primary adrenocortical insufficiency, in pregnancy, 278

Hydrolaparoscopy, transvaginal. *See* Transvaginal hydrolaparoscopy.

HydroThermAblator system, for abnormal uterine bleeding, 696–697

Hydrothorax, fetal, fetocentesis for, 116

17-α-Hydroxyprogesterone, monitoring of, in first trimester, 767–768

3β-Hydroxysteroid dehydrogenase, in genital tract formation, 846–847

17β-Hydroxysteroid dehydrogenase-3, in genital tract formation, 847

Hydroxyurea, for sickle cell syndromes, in pregnancy, 293

Hyperaldosteronism, primary, in pregnancy, 278

Hypercalcemia, in pregnancy, 275–276

Hypercortisolism, in pregnancy, 261–262

Hyperemesis gravidarum, and hyperthyroidism, 270

Hyperhomocysteinemia, in pregnancy, 327

Hyperparathyroidism, primary, in pregnancy, 275–276

Hypertension, in pregnancy, **223–241**
chronic hypertension, 235–237
antihypertensive medications for, 235–236
timing of delivery for, 236–237
with superimposed pre-eclampsia, 237–238

gestational hypertension, 237
mild pre-eclampsia and, 223, 226–228, 230
hospitalization versus home care for, 226–228
seizure prevention in, 228, 230
timing of delivery for, 228
severe pre-eclampsia and, 230–231, 234–235
antihypertensive medications for, 231, 234
in HELLP syndrome, 234
timing of delivery for, 231
maternal, and intrauterine growth restriction, 162–163

Hyperthyroidism, fetal and neonatal, 270–271
in pregnancy, 269–270, 896–899

Hypoglycemia, neonatal, maternal diabetes mellitus and, 918–919

Hypoparathyroidism, in pregnancy, 276–277

Hypopituitarism, in pregnancy, 262–263

Hypothalamic disorders, in pregnancy. *See* Endocrine disorders.

Hypothyroidism, fetal, 272–273
in pregnancy, 271–272, 900–901

Hysterectomy, alternatives to, 523–525
endometrial ablation, 525
levonorgestrel-releasing intrauterine system, 525
myomectomy, 524
resectoscopic myomectomy, 524
uterine artery embolization, 524
benefits of, 525–526
laparoscopic. *See* Laparoscopic hysterectomy.
robotic laparoscopic, 605–607

Hysteroscopic myomectomy, for fibroids. *See* Fibroids.

Hysteroscopy, in office. *See* Office hysteroscopy.
of abnormal uterine bleeding. *See* Abnormal uterine bleeding.

I

IgE blockers, for asthma, in pregnancy, 405

Immunoglobulin, intravenous, for antiphospholipid syndrome, in pregnancy, 365

Immunologic factors, in ectopic pregnancy, 784

Immunosuppressive agents, in pregnancy, after organ transplantation. *See* Organ transplantation.

Implantable cardioverter-defibrillators, in pregnancy, 447–448

Implantation, hormonal regulation of, **745–766**
androgens in, 757–758
calcitonin in, 756
cellular/molecular markers of, 749–755
cell adhesion molecules, 750–751
connexins, 755
cytokines, 751–752
growth factors, 754–755
homeobox genes, 752–754
pinopodes, 749
proteases and protease inhibitors, 755
endometrial receptivity in, 748–749
endometrium and menstrual cycle in, 746–747
human chorionic gonadotropin in, 756–757
in assisted reproductive technology cycles, 758
luteal phase defect in. *See* Luteal phase defect.
normal implantation, 745–746
prolactin in, 757
prostaglandins in, 755–756
steroid hormones, 747–748

Implantation window, in ectopic pregnancy, 780–781
luteal phase defect and, 737

Imuran, in pregnancy, after organ transplantation, 419

In vitro fertilization, luteal phase defect and, 736–737
with embryo cryopreservation, in fertility preservation, 612

Infections, congenital, echogenic bowel with, 65
hysteroscopic myomectomy and, 677
intrauterine, and intrauterine growth restriction, 162

Inferior vena cava, evaluation of, in intrauterine growth restriction, 167

Infertility, luteal phase defect and, 735–736
thalassemia syndromes and, 299–300

Inhibins, in screening, for Down syndrome, 858–859
monitoring of, in first trimester, 772–773

Insulin, in pregnancy, 250–251, 912–913, 922–923, 924

Insulin growth factor binding protein-1, monitoring of, in first trimester, 770

αvβ3 Integrin expression, luteal phase defect and, 737–739

Integrins, as markers, for implantation, 750

αvβ3 Integrins, as markers, for implantation, 750

Interleukins, as markers, for implantation, 751

Intra-amniotic bleeding, echogenic bowel with, 66

Intrauterine devices, in contraception, after organ transplantation, 423

Intrauterine growth restriction. *See* Fetal growth and well-being.

Iodine deficiency, in pregnancy, 266, 271
and hypothyroidism, 900

Ipratropium bromide, for asthma, in pregnancy, 403

Ischemic heart disease, in pregnancy, 445–446

Isoimmunization, amniocentesis and, 103
chorionic villus sampling and, 106

K

Kidneys, fetal biopsy of, 109
ultrasonography of, for fetal anomalies, 44–45

L

Lactation. *See* Breast-feeding.

Lactogen, human placental, in breast-feeding, 970–971

Lactogenesis, in breast-feeding, 966

Laparoscopic hysterectomy, **523–537**
complications of, 532–533
costs of, 534
large uterus and, 533
obesity and, 533
supracervical, 528–529
technique for, 529–532
training and credentialing in, 534–535
versus abdominal hysterectomy, 526–528
versus vaginal hysterectomy, 528

Laparoscopic lymphadenectomy, in uterine cancer. *See* Uterine cancer.

Laparoscopic myomectomy, as alternative to hysteroscopic myomectomy, 680

Laparoscopic sentinel node biopsy, in uterine cancer. *See* Uterine cancer.

Laparoscopic surgery, for endometriosis. *See* Endometriosis.
for ovarian cysts. *See* Ovarian cysts.
for ovarian remnants. *See* Ovarian remnants.
for pelvic floor prolapse. *See* Pelvic floor prolapse.
for urinary incontinence. *See* Urinary incontinence.
for uterine cancer. *See* Uterine cancer.
hysterectomy. *See* Laparoscopic hysterectomy.
in children and adolescents, **469–483**
for adnexal masses, 477–479
for appendicitis, 474–476
for chronic pelvic pain/endometriosis, 479–481
for pelvic inflammatory disease, 476–477
historical aspects of, 469
instrumentation for, 470–471
patient selection for, 471–472
technique for, 472–473
in fertility preservation. *See* Fertility preservation.
in second trimester, **485–496**
advantages of, 485–486
disadvantages of, 486
indications for, 486–487
physiologic changes and, 488–490
pneumoperitoneum and, 490–494
carbon dioxide in, 490, 492
carbon monoxide in, 493
needle placement in, 491
patient positioning in, 491–492
port placement in, 491
in tubal sterilization, 706–707
robotic. *See* Robotic laparoscopic surgery.

Large for gestational age infants. *See* Fetal growth and well-being, macrosomia.

Laser therapy, for abnormal uterine bleeding, 689–690

Left-to-right shunts, in pregnancy, 441

Leptin, monitoring of, in first trimester, 774

Leukemia inhibiting factor, as marker, for implantation, 751–752

Leukemia inhibitory factor, in ectopic pregnancy, 782

Leukotriene modifiers, for asthma, in pregnancy, 404

Levonorgestrel-releasing intrauterine system, as alternative to hysterectomy, 525

Loop electrocoagulation, for abnormal uterine bleeding, 690

Low-density lipoprotein, in steroid hormone synthesis, in pregnancy, 798

Low molecular weight heparin, for antiphospholipid syndrome, in pregnancy, 363–364
for mechanical heart valves, in pregnancy, 437, 439
for thromboembolic disease, in pregnancy, 336–338

Lung development, fetal. *See* Fetal lung development.

Lupus anticoagulant, in pregnancy, 328–329, 359–360

Lupus erythematosus, neonatal, maternal systemic lupus erythematosus and, 351–352

Luteal phase defect, **727–744,** 748–749
and endometrial receptivity, 737–738, 748–749
and implantation window, 737
and in vitro fertilization, 736–737
and infertility, 735–736
and lack of $\alpha v\beta 3$ integrin expression, 737–739
and recurrent abortion, 733–735
diagnosis of, 729–733
basal body temperature chart in, 729–730
endometrial histology in, 730–731, 732, 737
progesterone levels in, 731–733
ultrasonography in, 733
etiopathogenesis of, 728–729
luteinizing hormone in, 728–729, 731–732

Luteinizing hormone, and luteal phase defect, 728, 729, 731–732
in pregnancy, 881–882

Lymphadenectomy, laparoscopic, in uterine cancer. *See* Uterine cancer.

Lymphocytic hypophysitis, in pregnancy, 262–263

M

Macroangiopathy, diabetes mellitus and, 912

Macrophage inhibitory cytokine-1, monitoring of, in first trimester, 774

Macrophage migration inhibitory factor, monitoring of, in first trimester, 774

Macrosomia. *See* Fetal growth and well-being.

Magnesium sulfate, to prevent seizures, in pre-eclampsia, 228, 230

Magnetic resonance imaging, of deep vein thrombosis, in pregnancy, 333
of ovarian cysts, 583

Mammary gland, in breast-feeding, 963–965

Mammogenesis, in breast-feeding, 965–966

Marfan's syndrome, in pregnancy, 440–441

Matrix metalloproteinases, as markers, for implantation, 755

Maximum vertical pocket, in amniotic fluid measurement, 178

MCA-PSV measurement, of fetal hematocrit, 210

Mechanical heart valves, in pregnancy, 436–439

Medications, fetal transfusion of, 110

Menorrhagia. *See* Abnormal uterine bleeding.

Menstrual cycle, role of, in implantation, 746–747

Metabolic changes, in pregnancy, and laparoscopic surgery, 488–489

Methimazole, for Graves' disease, in pregnancy, 898
for thyroid storm, in pregnancy, 899

Methotrexate, for ectopic pregnancy, 789–790

Microangiopathy, diabetes mellitus and, 911–912

Microwave therapy, for abnormal uterine bleeding, 699–700

Middle cerebral artery, evaluation of, in intrauterine growth restriction, 166

Mineralocorticoids, and maternal adrenals, 829

Mitral regurgitation, in pregnancy, 435–436

Mitral stenosis, in pregnancy, 431–432, 434

Mitral valve prolapse, in pregnancy, 436

Molecular markers, for implantation. *See* Implantation.

Monoamniotic twins, ultrasonography of, 143–145

Monoclonal antibodies, for asthma, in pregnancy, 405

Montelukast, for asthma, in pregnancy, 404

MUC-1, as marker, for implantation, 750–751

Müllerian inhibiting substance, in genital tract formation, 843–844

Multiple gestations. *See also* Twin gestations.
amniocentesis in, 103
amniotic fluid volume in, 181
chorionic villus sampling in, 105–106
multifetal reduction for, 112–114
complications of, 113–114
historical aspects of, 112–113
safety of, 113–114
technique for, 113
transvaginal ultrasonography in, 134–135

Muscles, fetal biopsy of, 108–109

Mycophenolate mofetil, in pregnancy, after organ transplantation, 420

Myocardial infarction, in pregnancy, 445–446

Myomectomy, as alternative to hysterectomy, 524
hysteroscopic, for fibroids. *See* Fibroids.
laparoscopic, as alternative to hysteroscopic myomectomy, 680
robotic, 605–606
vaginal, as alternative to hysteroscopic myomectomy, 680

N

Nasal bone, fetal, in screening, for Down syndrome, 12–13

Nedocromil, for asthma, in pregnancy, 402

Neonatal hemorrhagic disease, maternal anticonvulsant therapy and, 377

Neonatal lupus erythematosus, maternal systemic lupus erythematosus and, 351–352

Nephritis, lupus, in pregnancy, 348–349, 356

Nephropathy, diabetes mellitus and, 911, 916

Neural tube defects, fetal, screening for, 868–869

Neurodevelopmental disorders, neonatal, maternal diabetes mellitus and, 919

Neurolytic procedures, for chronic pelvic pain, of uterine etiology, 625

Neuropathy, diabetes mellitus and, 912, 916–917

Neuropsychiatric systemic lupus erythematosus, in pregnancy, management of, 356

Nonsteroidal anti-inflammatory drugs, for systemic lupus erythematosus, in pregnancy, 353

NovaSure system, for abnormal uterine bleeding, 698–699

Nuchal cord, ultrasonography of, 185

Nuchal thickening, in Down syndrome, 25
in trisomy 13, 31

Nuchal translucency, in screening, for aneuploidy, 8
for Down syndrome. *See* Down syndrome.

Nutritional factors, in diabetes mellitus, in pregnancy, 248–249

O

Obesity, and laparoscopic hysterectomy, 533

Office hysteroscopy, **641–654**
diagnostic, 644–646
targeted biopsies in, 644–645
historical aspects of, 641–642
in advanced bipolar surgery, 649–652
materials and methods in, 649–650
patient selection for, 650–651
results of, 651–652
technique for, 651
in traditional mechanical surgery, 646–649
materials and methods in, 647
results of, 647–648
recent developments in, 642–643
to evaluate uterine cavity, 643–644
vaginoscopic approach to, 643

Oligohydramnios, ultrasonography of, 178–180
in stuck twin, 147–148

Omalizumab, for asthma, in pregnancy, 405

Omphalocele, in trisomy 18, 28–29

Oocytes, cryopreservation of, in fertility preservation, 612
in vitro maturation of, in fertility preservation, 612

Oral contraceptives, after organ transplantation, 423
for ovarian cysts, 583–584

Organ transplantation, breast-feeding after, 427
contraception after, 422–423
barrier methods in, 422
intrauterine devices in, 423
oral contraceptives in, 423
progesterone-only contraceptives in, 423

pregnancy after, **415–428**
immunosuppressive agents in, 416–421
and birth defects, 417
azathioprine, 419
cyclosporin A, 419–420
FDA categories of, 417
mycophenolate mofetil, 420
sirolimus, 420–421
steroids, 418–419
tacrolimus, 420
types of, 417
laboratory tests in, 426
National Transplant Pregnancy Registry summary on, 425
outcomes of, 423–425
preconception counseling for, 421–422
timing of delivery for, 426–427

Osteopontin, as marker, for implantation, 750

Osteoporosis, pregnancy and, 277

Ovabloc system, in tubal sterilization, 709

Ovarian capsule drilling, transvaginal hydrolaparoscopy in, 636–637

Ovarian cryopreservation, laparoscopic, in fertility preservation, 614–615

Ovarian cysts, aspiration of, 583
laparoscopic surgery for, **581–592,** 623
for benign cystic teratomas, 590
intraoperative evaluation in, 584–585
preoperative evaluation for, 584
rationale for, 581–582
technique for, 585–586, 588–589
tissue removal in, 588–589
magnetic resonance imaging of, 583
oral contraceptives for, 583–584
physical examination for, 582
serum markers for, 583
ultrasonography of, 582–583

Ovarian differentiation, fetal hormones and. *See* Sexual differentiation.

Ovarian remnants, **593–597**
diagnosis of, 594–595
laparoscopic surgery for, 595–596, 623–624
pathogenesis of, 593–594
prevention of, 595

Ovarian transposition, laparoscopic, in fertility preservation, 613–614

Ovarian vein thrombosis, in pregnancy, 336

Oxytocin, in breast-feeding, 972–974

P

Pain mapping, laparoscopic, in chronic pelvic pain, 626–627

Parathyroid diseases, in pregnancy, 275–277

Paravaginal repair, of cystoceles, 562–563

Paroxysmal supraventricular tachycardia, in pregnancy, 447

Parturition, initiation of at term, **935–947**
fetal control of, 937–943
corticotropin-releasing hormone in, 937–938
cortisol in, 939–940
estrogen in, 940–942
pathologic mechanisms in, 942–943
prostaglandins in, 936
versus other species, 935–936
regulation of, fetal adrenal/placental steroids in, 824

Patent ductus arteriosus, in pregnancy, 442

P-block, in tubal sterilization, 709–710

P450C17, in genital tract formation, 846

Pelvic floor prolapse, laparoscopic surgery for, **551–565**
cystocele repair, 561–563
paravaginal technique for, 562–563
results of, 563
rectocele repair, 563–564
results of, 557, 560
sacral colpopexy, 555–557, 607
site-specific enterocele repair and vaginal vault suspension, 554
uterosacral-ligament vault suspension and enterocele repair, 554–555
pelvic support anatomy in, 551–554
apical support, 552–553
distal support, 554
endopelvic fascia, 551–552
lateral support, 553

Pelvic inflammatory disease, and ectopic pregnancy, 783
laparoscopic surgery for, in children and adolescents, 476–477

Pelvic pain, chronic. *See* Chronic pelvic pain.

Percutaneous umbilical blood sampling. *See* Cordocentesis.

Phenylpropylthiouracil, for Graves' disease, in pregnancy, 897–898

Pheochromocytomas, and maternal adrenals, 831
in pregnancy, 279–280

Pinopodes, as markers, for implantation, 749

Pituitary disorders, in pregnancy. *See* Endocrine disorders.

Pituitary gland, in pregnancy, **873–892**
anatomy of, 873–875
and corticotropin, 878–879
and gonadotropins, 881–882
and growth hormone, 879–880
and prolactin, 877–878
and thyroid-stimulating hormone, 880–881
embryology of, 874

Placenta, Doppler ultrasonography of, 196–197
ultrasonography of, 190–197
for abnormalities of location, 192–193
for abnormalities of shape, 191–192
for abruption, 194
for gestational trophoblastic disease, 195–196
for masses, 194–195

Placental biopsy, chorionic villus sampling in, 106

Placental corticotropin-releasing hormone, and fetal adrenals, 821–822

Placental enzyme deficiencies, and fetal adrenals, 826–827

Placental estrogen biosynthesis, fetal adrenals and, 822–824

Placental lactogen, in breast-feeding, 970–971

Placental mosaicism, chorionic villus sampling and, 105

Plasma protein-A, in screening, for Down syndrome, 865–866
monitoring of, in first trimester, 770–772

Plasminogen activators, in ectopic pregnancy, 784–785

Platelet transfusions, fetal, 110

Pleural effusions, fetal, fetocentesis for, 116

Pneumoperitoneum, in laparoscopic surgery, in second trimester. *See* Laparoscopic surgery.

Polydactyly, in trisomy 13, 30

Polyhydramnios, fetal, maternal diabetes mellitus and, 918
ultrasonography of, 180–181

Potassium chloride injection, in multifetal reduction, 112–113
in selective termination, 115

Prednisone, for antiphospholipid syndrome, in pregnancy, 361–362

Pre-eclampsia, and hypertension.
See Hypertension.
antiphospholipid antibodies in, 358
diabetes mellitus and, 917
systemic lupus erythematosus and, 349–350

Pregnancy, adrenals in. *See* Adrenals.
after organ transplantation.
See Organ transplantation.
antiphospholipid syndrome in.
See Antiphospholipid syndrome.
asthma in. *See* Asthma.
autoimmune disease in.
See Antiphospholipid syndrome; Systemic lupus erythematosus.
cardiac disease in. *See* Cardiac disease.
cardiovascular system in. *See* Cardiovascular system.
diabetes mellitus in. *See* Diabetes mellitus.
ectopic. *See* Ectopic pregnancy.
endocrine disorders in. *See* Endocrine disorders.
first trimester of, hormonal monitoring of, **767–778**
activin, 769
carcinoembryonic antigen, 769
estrogen, 768
human chorionic gonadotropin, 768–769
inhibins, 772–773
insulin growth factor binding protein-1, 770
leptin, 774
macrophage inhibitory cytokine-1, 774
macrophage migration inhibitory factor, 774
plasma protein-A, 770–772
progesterone and 17-α-hydroxyprogesterone, 767–768
hemoglobinopathies in.
See Hemoglobinopathies.
hypertension in. *See* Hypertension.
pituitary gland in. *See* Pituitary gland.
seizure disorders in. *See* Seizure disorders.
steroid hormone synthesis in. *See* Steroid hormone synthesis.
systemic lupus erythematosus in.
See Systemic Lupus erythematosus.
thromboembolic disease in. *See* Thromboembolic disease.
thyroid disease in.
See Endocrine disorders.

Pregnancy-associated plasma protein, in screening, for Down syndrome, 9, 154–155

Pregnanediol glucuronide levels, in luteal phase defect, 733

Preterm delivery, cerclage placement for, 130, 134, 152
cervical length and, in multiple gestations, 134–135, 151–152
diabetes mellitus and, 917
predictors of, 125, 130–131, 133–134
screening for, transabdominal ultrasonography in, 126
transvaginal ultrasonography in, **125–139**
cervical length in, 127, 129–131, 133–134, 151–152
cervical stress test in, 128–129
funneling in, 128
in multiple gestations, 134–135
technique for, 126–129

Primordial germ cell migration, in sexual differentiation, 838–839

Progesterone, in ectopic pregnancy, 787
in luteal phase defect, 731–733
in steroid hormone synthesis, in pregnancy, 798
monitoring of, in first trimester, 767–768

Progesterone-only contraceptives, after organ transplantation, 423

Progesterone receptors, role of, in implantation, 747–748

Prograf, in pregnancy, after organ transplantation, 420

Prolactin, in breast-feeding, 966–970
dopamine and, 968
in pregnancy, 877–878
role of, in implantation, 756–757

Prolactinomas, in pregnancy.
See Endocrine disorders.

Propylthiouracil, for Graves' disease, in pregnancy, 269–270
for thyroid storm, in pregnancy, 899

Prostaglandins, and initiation of parturition, at term, 936
role of, in implantation, 755–756

Protease inhibitors, as markers, for implantation, 755

Proteases, as markers, for implantation, 755

Protein C deficiency, in pregnancy, 324–325

Protein S deficiency, in pregnancy, 325–326

Prothrombin 20210A, in pregnancy, 327–328

Pulmonary embolism, in pregnancy, 333, 336

Pulmonary function tests, for asthma, in pregnancy, 395, 397, 400

Pulmonary valves, fetal, Doppler velocimetry of, 210

Pulmonic stenosis, in pregnancy, 435

Pulsed Doppler ultrasonography, of twin-to-twin transfusion syndrome, 148

Pyelectasis, fetal, clinical features of, 69–70
diagnosis of, 68–69
management of, 72–73
prognosis for, 71–72
ultrasonography of, 27, 44–45, 67–73
with aneuploidy, 69, 70
with postnatal renal abnormalities, 71

Q

Quad screen, for Down syndrome, 1

Quinacrine, in tubal sterilization, 708–709

R

Radiation therapy, fertility preservation after, 611

Radioactive iodine therapy, in pregnancy, 268

RADIUS trial, of ultrasonography, of fetal anomalies, 36–38, 52–53

Rectoceles, laparoscopic surgery for, 563–564

Renal abnormalities, in trisomy 13, 30
postnatal, pyelectasis with, 71

Renal artery, fetal, Doppler velocimetry of, 205

Renal disease, systemic lupus erythematosus and, in pregnancy, 348–349, 356

Renal failure, diabetes mellitus and, 911

Respiratory distress syndrome, neonatal, antenatal glucocorticoids and, 952
maternal diabetes mellitus and, 252, 919

Retinopathy, diabetes mellitus and, 911–912, 915–916

Rigid hysteroscopy, of abnormal uterine bleeding, 663

Robotic laparoscopic surgery, **599–609**
adnexectomy, 605

AESOP system in, 600
components of, 599
da Vinci system in, 600, 601–602, 605–607
hysterectomy, 605–607
learning curve for, 602–603
myomectomy, 605–606
sacral colpopexy, 607
telesurgery in, 607–608
versus conventional laparoscopic surgery, 604
Zeus system in, 600, 601

Rollerblade electrocoagulation, for abnormal uterine bleeding, 690–692

S

Sacral colpopexy, laparoscopic technique for, 555–557
robotic, 607

Salpingectomy, for ectopic pregnancy, 790–791

Salpingotomy, for ectopic pregnancy, 790–791

Sandimmune, in pregnancy, after organ transplantation, 419–420

Seizure disorders, and breast-feeding, 380–381
in pregnancy, **373–384**
effects of antiepileptic drugs on fetus, 374–377
folic acid supplementation for, 379
maternal alpha-fetoprotein screening for, 379
monitoring drug levels in, 380
preconceptional counseling for, 378–381
pregnancy effects on, 373–374
prenatal care for, 378–381
prevention of, in pre-eclampsia, 228, 230

Selective termination, 114–115
complications of, 115
historical aspects of, 114–115
of monochorionic twins, 115
safety of, 115
technique for, 115

Sentinel node biopsy, laparoscopic, in uterine cancer. *See* Uterine cancer.

Septic pelvic thrombophlebitis, in pregnancy, 336

Septostomy, in twin gestations, 112

Serum markers, for ovarian cysts, 583

Sex determining region, in testicular differentiation, 840–841

Sexual differentiation, fetal hormones and, **837–856**
formation of bipotential gonad, 838
genital tracts, 843–850
cholesterol 20,22-desmolase in, 846
dihydrotestosterone in, 849–850
17β-hydroxysteroid dehydrogenase-3 in, 847
3β-hydroxysteroid dehydrogenase in, 846–847
müllerian inhibiting substance in, 843–844
P450C17 in, 846
steroid acute regulatory protein in, 846
testosterone in, 845
ovarian differentiation, 842–843
Dax-1 in, 842–843
embryology of, 842
primordial germ cell migration, 838–839
testicular differentiation, 840–841
Dax-1 in, 841
embryology of, 840
sex determining region in, 840–841
Sox9 in, 841
steroidogenic factor-1 in, 841
Wilms' tumor suppressor-1 in, 841

Sheehan's syndrome, in pregnancy, 262, 885–886

Shoulder dystocia, in infants, maternal diabetes mellitus and, 252–253, 918
macrosomia and, 169–170, 918

Shunt procedures, vesicoamniotic. *See* Vesicoamniotic shunt procedures.

Sickle cell syndromes, in pregnancy. *See* Hemoglobinopathies.

Single umbilical artery, and pregnancy outcome, 83, 85
diagnosis of, 81–83
management of, 85–86
ultrasonography of, 81–83, 85–86, 186–187
versus umbilical artery fusion, 81–82

Singulair, for asthma, in pregnancy, 404

Sirolimus, in pregnancy, after organ transplantation, 420–421

Skeletal abnormalities, in trisomy 18, 28

Skin, fetal biopsy of, 109

Slings, for urinary incontinence. *See* Urinary incontinence.

Smoking, and ectopic pregnancy, 785–786

Somatomammotropin, human chorionic, in breast-feeding, 970–971

Sox9, in testicular differentiation, 841

Sperm defects, and ectopic pregnancy, 786

Spina bifida, fetal, screening for, 868

Spine, ultrasonography of, for fetal anomalies, 45

Splenic artery, fetal, Doppler velocimetry of, 205

Sterilization, tubal. *See* Tubal sterilization.

Steroid hormone synthesis, in pregnancy, **795–816**
- cholesterol availability in, 801–803
- cholesterol molecule in, 797–799
- controversies in, 806–807
- cytochrome P450 in, 797–798, 801–803
- estrogen in, 798
- high-density lipoprotein in, 799
- human chorionic gonadotropin in, 798
- low-density lipoprotein in, 798
- progesterone in, 798
- steroidogenic acute regulatory protein in, 801, 802
- steroidogenic pathways in, 803–806
- substrate for, 797–799

Steroidogenic acute regulatory protein, in genital tract formation, 846
- in steroid hormone synthesis, in pregnancy, 801, 802

Steroidogenic enzymes, in fetal adrenals, 818–820

Steroidogenic factor-1, in testicular differentiation, 841

Steroids, for antiphospholipid syndrome, in pregnancy, 361–362
- for HELLP syndrome, 234
- for systemic lupus erythematosus, in pregnancy, 353
- in pregnancy, after organ transplantation, 418–419
- inhaled, for asthma, in pregnancy, 402–403
- systemic, for asthma, in pregnancy, 405

Stomach, ultrasonography of, for fetal anomalies, 43

Strawberry-shaped head, in trisomy 18, 28

Stuck twin, ultrasonography of, 146–148

Succenturiate lobe, ultrasonography of, 191

Sulfonylurea drugs, for diabetes mellitus, in pregnancy, 251

Superior cerebellar artery, fetal, Doppler velocimetry of, 206

Superior mesenteric artery, fetal, Doppler velocimetry of, 205

Supracervical hysterectomy, rationale for, 528–529

Systemic lupus erythematosus, in pregnancy, 346–356
- diagnostic criteria for, 347
- fetal outcome in, 350–352
  - fetal growth restriction, 350
  - neonatal lupus erythematosus, 351–352
  - pregnancy loss, 350
  - preterm birth, 351
- management of, 352–356
  - for flares, 356
  - medications in, 353, 355
- maternal outcome in, 347–350
  - lupus flare, 347–348
  - pre-eclampsia, 349–350
  - renal disease, 348–349

T

Tacrolimus, in pregnancy, after organ transplantation, 420

Talipes equinovarus. *See* Clubfoot.

Teratomas, benign cystic, laparoscopic surgery for, 590

Termination, selective. *See* Selective termination.

Testicular differentiation, fetal hormones and. *See* Sexual differentiation.

Testosterone, in genital tract formation, 845, 850

Thalassemia syndromes, in pregnancy. *See* Hemoglobinopathies.

Theca lutein cysts, ultrasonography of, 195–196

Theo-dur, for asthma, in pregnancy, 403–404

Theophylline, for asthma, in pregnancy, 403–404

Thermablate EAS system, for abnormal uterine bleeding, 695–696

ThermaChoice systems, for abnormal uterine bleeding, 692–694

Thermal methods, in tubal sterilization, 708

Thoracic-amniotic shunt procedures, technique for, 118–119

Thorax, ultrasonography of, for fetal anomalies, 42–43

Three-dimensional ultrasonography, of macrosomia, 170–171

Thrombocytopenia, alloimmune, fetal platelet transfusion for, 110
antiphospholipid syndrome and, in pregnancy, 359

Thromboembolic disease, in pregnancy, **319–344**
activated protein C resistance/factor V Leiden, 326
antithrombin III deficiency, 324
deep vein thrombosis, 332–333
dysfibrinogenemia, 328
genetic/inherited coagulopathies/thrombophilia, 323
hemostasis in, 320–321
hyperhomocysteinemia, 327
incidence of, 319–320
lupus anticoagulant/antiphospholipid syndrome, 328–329, 359–360
ovarian vein thrombosis/septic pelvic thrombophlebitis, 336–339
pathophysiology of, 321–323
postpartum care for, 340
protein C deficiency, 324–325
protein S deficiency, 325–326
prothrombin 20210A, 327–328
pulmonary embolism, 333, 336
superficial thrombophlebitis, 332
thrombophilia, and intrauterine growth restriction, 163
congenital, 323–324
management of, 329, 332
screening for, 329
timing of delivery for, 339–340

Thrombophilia, in pregnancy. *See* Thromboembolic disease.

Thrombophlebitis, in pregnancy, 332, 336

Thromboprophylaxis, for antiphospholipid syndrome, in pregnancy, 365

Thrombosis, antiphospholipid syndrome and, in pregnancy, 358–359

Thyroid cancer, in pregnancy, 903–904

Thyroid disease, in pregnancy. *See* Endocrine disorders.

Thyroid hormones, and fetal lung development, 950–951

Thyroid storm, in pregnancy, 899

Thyroidectomy, for Graves' disease, in pregnancy, 898–899

Thyroiditis, postpartum, 901–902

Thyroid-stimulating hormone, in pregnancy, 880–881

Thyrotoxicosis, in neonates, maternal Graves' disease and, 898

Thyrotropin-releasing hormone, and fetal lung development, 957–958

Thyroxine, and fetal lung development, 951
for hypothyroidism, in pregnancy, 272, 901

Tissue inhibitors of matrix metalloproteinases, as markers, for implantation, 755

Transabdominal ultrasonography, in screening, for preterm delivery, 126

Transcervical resection, for abnormal uterine bleeding, 690

Transfusions, fetal. *See* Fetal transfusions.

Transplantation, organ. *See* Organ transplantation.

Transvaginal hydrolaparoscopy, **631–639**
advantages of, 634
complications of, 633–634
failure of, 633
findings in, 633
for endometriosis, 635–636
in ovarian capsule drilling, 636–637
instrumentation for, 635
patient acceptance of, 634
rationale for, 637–638
technique for, 632, 635–636

Transvaginal tape, for urinary incontinence, 546

Transvaginal ultrasonography, in screening, for preterm delivery. *See* Preterm delivery.
of ovarian cysts, 582–583

Triiodothyronine, and fetal lung development, 951

Triplet gestations, multifetal reduction in, 114
transvaginal ultrasonography of, 134–135

Trisomy 13. *See* Aneuploidy.

Trisomy 18. *See* Aneuploidy.

Trisomy 21. *See* Down syndrome.

Trophoblast antigen, in screening, for Down syndrome, 861–863

Trophoblast invasion, in ectopic pregnancy, 784–785

Tubal sterilization, **705–719**
chemicals in, 708–709
cryocoagulation in, 708
electrocoagulation in, 707–708
historical aspects of, 705–706
intratubal mechanical devices in, 709–717
Essure system, 714–717
irreversibility of, 717
nickel allergy in, 716
formed-in-place devices, 709–710
premolded devices, 711
tubal screws, 711–714
laparoscopic, 706–707
thermal methods in, 708
transuterine, early attempts at, 707

Twin gestations. *See also* Multiple gestations.
appearing twin phenomenon in, 143
diagnosis of, 142–143
etiology of, 141–142
nuchal translucency screening in, 8
placentation in, 143
transvaginal ultrasonography of, 134–135
ultrasonography of, **141–158**
acardiac twins, 150–151
conjoined twins, 145–146
for aneuploidy, 152–156
for cervical length and spontaneous preterm delivery, 151–152
for Down syndrome, 152–155
for twin-to-twin transfusion syndrome, 148–150
intrapartum, 156
monoamniotic twins, 143–145
stuck twin, 146–148
vanishing twin phenomenon in, 142–143

Twin-to-twin transfusion syndrome, ultrasonography of, 148–150

U

Ultrasonography, in amniocentesis. *See* Amniocentesis.
in amnioreduction. *See* Amnioreduction.
in chorionic villus sampling. *See* Chorionic villus sampling.
in cord occlusion procedures, 119
in cordocentesis. *See* Cordocentesis.
in fetal biopsy. *See* Fetal biopsy.
in fetal transfusions. *See* Fetal transfusions.
in fetocentesis, 115–116
in hysteroscopic myomectomy, 678
in in utero balloon valvuloplasty, 119
in multifetal reduction. *See* Multiple gestations.
in screening, for aneuploidy. *See* Aneuploidy.
for Down syndrome. *See* Down syndrome.
for fetal anomalies. *See* Fetal anomalies.
for hemoglobinopathies, in pregnancy, 307–308
for preterm delivery. *See* Preterm delivery.
in selective termination. *See* Selective termination.
in septostomy, 112
in vesicoamniotic shunt procedures. *See* Vesicoamniotic shunt procedures.
of amniotic fluid. *See* Amniotic fluid.
of choroid plexus cysts. *See* Choroid plexus cysts.
of clubfoot. *See* Clubfoot.
of deep vein thrombosis, in pregnancy, 333
of echogenic bowel. *See* Echogenic bowel.
of echogenic intracardiac foci. *See* Echogenic intracardiac foci.
of fetal membranes. *See* Fetal membranes.
of fetus, in asthmatic patients, 400
in diabetic patients, 251
of intrauterine growth restriction, 162–164
of luteal phase defect, 733
of macrosomia, 170–171
of ovarian cysts, 582–583
of ovarian remnants, 594–595
of placenta. *See* Placenta.
of pyelectasis. *See* Pyelectasis.
of single umbilical artery. *See* Single umbilical artery.
of twin gestations. *See* Twin gestations.
of umbilical cord. *See* Umbilical cord.

Umbilical artery, evaluation of, in intrauterine growth restriction, 165–166
single. *See* Single umbilical artery.

Umbilical artery fusion, versus single umbilical artery, 81–82

Umbilical blood flow, Doppler velocimetry of, 203

Umbilical blood sampling, percutaneous. *See* Cordocentesis.

Umbilical cord, ultrasonography of, 183–190
for abdominal wall defects, 188
for abnormalities of insertion, 187–188
for fetal anomalies, 47–48
for masses, 188–190
for nuchal cord, 185

Urea-resistant neutrophil alkaline phosphatase, in screening, for Down syndrome, 861

Urinary incontinence, laparoscopic surgery for, **539–549**
Burch procedures in, 539–544
extraperitoneal approach to, 539–542
intraperitoneal approach to, 542–543
slings in, 544–546
extraperitoneal approach to, 544–545
intraperitoneal approach to, 545
transvaginal tape in, 546

Urinary tract, ultrasonography of, for fetal anomalies, 44–45

Urologic complications, of sickle cell syndromes, in pregnancy, 294–295

Uterine artery embolization, as alternative to hysterectomy, 524
as alternative to hysteroscopic myomectomy, 679–680

Uterine bleeding, abnormal. *See* Abnormal uterine bleeding.

Uterine cancer, laparoscopic lymphadenectomy in, 505–509
feasibility of, 507–508
safety of, 508
technique for, 506–507
versus open procedure, 508–509
laparoscopic sentinel node biopsy in, 509–518
assessing nodes in, 515–517
locating and removing nodes in, 512, 514–515
rationale for, 517–518
targeting nodes in, 509, 512

Uterine cavity, hysteroscopy of, 643–644

Uterine perforation, hysteroscopic myomectomy and, 676

Uterine rupture, hysteroscopic myomectomy and, 677

V

Vacuum bottle method, of therapeutic amniocentesis, for twin-to-twin transfusion syndrome, 150

Vaginal apex pain, laparoscopic surgery for, 624–625

Vaginal hysterectomy, versus laparoscopic hysterectomy, 528

Vaginal myomectomy, as alternative to hysteroscopic myomectomy, 680

Vaginal vault suspension, laparoscopic technique for, 554–557, 560

Vaginoscopic approach, to hysteroscopy, 643

Valproic acid, for seizure disorders, fetal effects of, 375–376

Valvular heart disease, in pregnancy, 431

Valvuloplasty, balloon, in utero, technique for, 119

Vanishing twin phenomenon, ultrasonography of, 142–143

Varicosities, pelvic, laparoscopic surgery for, 626
umbilical cord, ultrasonography of, 189–190

Vasa previa, ultrasonography of, 187–188

Vascular disease, maternal, and intrauterine growth restriction, 162–163

Vasopressin deficiency, in pregnancy, 263–264

Velamentous cord insertion, ultrasonography of, 187

Velocimetry, Doppler. *See* Doppler velocimetry.

Venous system, fetal, in intrauterine growth restriction, 206

Ventricles, lateral, ultrasonography of, for fetal anomalies, 39–40

Ventricular outflow tract views, in screening, for congenital heart disease, 54–55

Ventricular septal defects, in Down syndrome, 23
in pregnancy, 442

Ventricular tachycardia, in pregnancy, 447–448

Vesicoamniotic shunt procedures, 116–119
complications of, 117
technique for, 117–119

Vesicocentesis, technique for, 115–116

Virilization, in pregnancy, 280

W

Wall suction method, of therapeutic amniocentesis, for twin-to-twin transfusion syndrome, 150

Warfarin, for mechanical heart valves, in pregnancy, 436–437
for thromboembolic disease, in pregnancy, 338–339

Wilms' tumor suppressor-1, in testicular differentiation, 841

Z

Zafirlukast, for asthma, in pregnancy, 404

Zeus system, in robotic laparoscopic surgery, 600, 601